Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* A male or female between 18 and 40 years of age, inclusive, at the time of first vaccination.~* Written informed consent obtained from the subject.~* Healthy subjects as established by medical history, clinical examination and laboratory assessment before entering into the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test at Screening, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.~* Any clinically significant acute or chronic, local or systemic infection, proven or suspected to be caused by Staphylococcus aureus and requiring antibiotic treatment, within the 6 months preceding the first vaccination.~* Previous administration of any investigational Staphylococcus aureus vaccine/antibodies.~* History of; or current bleeding or coagulation disorder.~* Known or suspected reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* History of; or current autoimmune or other immune-mediated disease.~* Administration or planned administration, of any vaccine not foreseen by the study protocol within 30 days of the first dose of vaccines up to 1 month after the last vaccine dose.~* Administration of immunoglobulins and/or any blood products within the last 3 months preceding the first dose of study vaccine or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* Any clinically relevant abnormal haematological or biochemical or urine laboratory values at screening.~* Any acute or chronic, clinically significant disease, as determined by physical examination or laboratory screening tests.~* Acute disease and/or fever at study entry.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of; or current alcoholism and/or drug abuse.~* Any other condition that the principal investigator judges may interfere with study findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: EXPERIMENTAL): None
- Group C (Type: EXPERIMENTAL): None
- Group D (Type: EXPERIMENTAL): None
- Group E (Type: PLACEBO_COMPARATOR): None
- Group F (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete